

REMARKS

Applicants note at the onset that the Reply/Preliminary Amendment filed on December 20, 2004 was not fully responsive to the prior Office Action because the status of claims 31-36 were listed as "New" when the status should have indicated "Canceled." The "New" claims that Applicant respectfully requests consideration of herein should have been numbered 37-43, but a typographical error resulted in a miss-numbering of these claims. Applicants apologize for any confusion and inconvenience made by the Preliminary Amendment document previously submitted on December 20, 2004 and confirm that the Reply filed herewith lists all current claims 21-25, 27-30 and new claims 37-43.

In response to an Office Action of March 21, 2005, Applicants respectfully request consideration of amended claims 21-25, 27-30 and new claims 37-43, which have not been fully and finally substantively examined. The pending claims are drawn to the use of a third binding moiety produced by a transgenically produced multivalent polypeptide. No claims are amended herein. Claims 1-20 and 26 were canceled in the Response filed December 20, 2004 and Claims 31-36 were canceled in the Response filed May 26, 2004. New claims 37-43 are added herein. Consideration of pending Claims 21-25, 27-30 and 37-43 is hereby requested.


New claims 31 through 37, being dependent upon and further limiting independent amended claims 21 and 27 (as the case may be), should also be allowable for that reason, as well as for the additional recitations they contain. Applicants respectfully request favorable consideration of these new claims in view of the above amendments and remarks.

The Commissioner is authorized to charge any fee which may now or hereafter be due for this application to GTC Biotherapeutics' Deposit Account No. 502092.

Applicants respectfully submit that the pending claims of this Amendment are in condition for allowance, and that this case is now in condition for allowance of all pending claims. Such action is thus respectfully requested. If the Examiner disagrees, or believes for any other reason that direct contact with Applicant's attorney would advance the prosecution of the case to finality, the Examiner is invited to telephone the undersigned at the number given below.

Early and favorable action is earnestly solicited.

Date: 3/24/05

Respectfully Submitted,

By: Byron V. Olsen
Byron V. Olsen, Reg. No. 42,960
ATTORNEY FOR APPLICANTS
GTC Biotherapeutics, Inc.
175 Crossing Blvd., Suite 410
Framingham, MA 01702
Tel. # (508) 370-8150
Fax # (508) 370-3797